Neuropeptide Y: an overview of central distribution, functional aspects, and possible involvement in neuropsychiatric illnesses.
Neuropeptide Y (NPY) was first discovered and characterized as a 36-amino-acid peptide neurotransmitter in 1982. It is widely distributed in the central nervous system, with particularly high concentrations within several limbic and cortical regions. A number of co-localizations with other neuromessengers such as noradrenaline, somatostatin, and gamma-aminobutyric acid have been demonstrated. A large number of physiological and pharmacological actions of NPY have been suggested. Recent clinical data also suggest the involvement of NPY in several neuropsychiatric illnesses, particularly in depressive and anxiety states. This article gives a comprehensive review of central distribution of NPY and its receptors, co-localizations and interactions with other neuromessengers, genetic aspects, pharmacological and physiological actions, influence on neuroendocrine functions, and possible involvement in various neuropsychiatric illnesses.
Heilig
M
M
Department of Psychiatry and Neurochemistry, University of Lund, Sweden.
Widerlöv
E
E
D000818:Animals; D001522:Behavior, Animal / Q000502:physiology*; D001921:Brain / Q000503:physiopathology*; D001931:Brain Mapping; D006801:Humans; D019965:Neurocognitive Disorders / Q000503:physiopathology*; D009478:Neuropeptide Y / Q000502:physiology*; D017476:Receptors, Neuropeptide Y; D017981:Receptors, Neurotransmitter / Q000502:physiology*; D009435:Synaptic Transmission / Q000502:physiology*
D009478:Neuropeptide Y; D017476:Receptors, Neuropeptide Y; D017981:Receptors, Neurotransmitter